Posted by Michael Wonder on 02 Jun 2024
Mirum Pharmaceuticals announces positive CHMP opinion for Livmarli (maralixibat) oral solution for the treatment of PFIC in patients three months of age and older
31 May 2024 - Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p<0.0001) reduction in pruritus severity between Livmarli versus placebo across all progressive familial intrahepatic cholestasis types studied.
Mirum Pharmaceuticals today announced that the CHMP has adopted a positive opinion of Livmarli (maralixibat) oral solution for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
